Colchicine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Colchicine

Examples of brand names: Colchicum-Dispert [DE]

ATC code: M04AC01

Main use (for orientation): Gout; autoinflammatory diseases

Documented research summary

No isolated colchicine pharmacokinetic interaction with CBD/THC demonstrated. A 2026 phase II study (n=27) used pharmaceutical CBD on stable NSAID/colchicine/corticosteroid background therapy; improvement and one serious event leading to discontinuation, but no randomised or colchicine-specific interaction analysis. Two 2019 FMF cannabis cases describe symptomatic improvement after colchicine resistance, but no concentration measurement or reliably isolated colchicine interaction. A 2026 secondary review does not replace original pair data.

Uncertainties and limitations

The pericarditis full text was directly blocked by browser verification; abstract and indexed original excerpts read, with no colchicine-specific pharmacokinetic/safety figures claimed. High toxicity/narrow safety margin establishes relevance, not the existence of a confirmed CBD pair effect.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

Pharmaceutically manufactured oral CBD – insufficient evidence

Finding ID: B0161

Type of result: Co-medication context without an isolated interaction

Observation: An open-label pericarditis study with stable concomitant NSAID/colchicine/corticosteroid therapy reported clinical improvement; one serious event led to CBD discontinuation. No colchicine-specific interaction analysis.

Mechanism: Co-medication context, not an isolated pharmacokinetic interaction

Study type: Open-label phase II study

Context studied: n=27; 8 weeks plus an optional 18-week extension with tapering of background therapy.

Clinical interpretation: Informational context; do not interpret as pair safety or synergy

Limitations and uncertainties: No control group/colchicine pharmacokinetics; accessible abstract and original excerpts, not a fully accessible full text.

Original sources for this finding: Efficacy and Safety of Pharmaceutically Manufactured Cannabidiol in Recurrent Pericarditis: A Phase II Clinical Trial. [CA_P_42432451]

References and access status

[CA_L_D0173] LODOCO (COLCHICINE TABLETS 0.5 MG) TABLET [AGEPHA PHARMA USA, LLC]

Original source / bibliographic reference

Authors: AGEPHA Pharma USA, LLC

Year: 2026

Source type: Official human-use SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_L_D0173_COLCRYS] COLCRYS (COLCHICINE) TABLET, FILM COATED [PROFICIENT RX LP]

Original source / bibliographic reference

Authors: Proficient Rx LP

Year: 2022

Source type: Official human-use SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_42432451] Efficacy and Safety of Pharmaceutically Manufactured Cannabidiol in Recurrent Pericarditis: A Phase II Clinical Trial.

Original source / bibliographic reference

Authors: Luis SA, Klein AL, Cremer PC, Abbate A, Salik JR, Thomas GK, Haider SW, Hagerty TE, Lin D, Waggoner TE, Nicholls SJ, Kirwan BA, Narine KAD, Parker AB, Hamer A.

Year: 2026

Source type: Primary / secondary publication; design and use described in the individual review

DOI: 10.1161/jaha.125.047605

PMID: 42432451

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CA_P_31501406] Medical Cannabis in Treatment of Resistant Familial Mediterranean Fever.

Original source / bibliographic reference

Authors: Habib G, Levinger U.

Year: 2019

Source type: Primary / secondary publication; design and use described in the individual review

DOI: 10.12659/ajcr.917180

PMID: 31501406

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility